Last checked at 18 Jan 2016 14:33
For immediate release | 18 January 2016 |
Futura Medical plc
("Futura" or "the Company")
Notice of Preliminary Results
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will announce its preliminary results for the year ended 31 December 2015 on Tuesday 15 March 2016.
A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
There will be a webcast of the analyst presentation. If you would like to listen to the webcast, please log on to the following web address approximately 5 minutes before 10.00am on the day of results:
http://vm.buchanan.uk.com/2016/futuramedical150316/registration.htm
A recording of the webcast will also be made available at www.futuramedical.com and www.buchanan.uk.com, following the results meeting. For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
Adoption of Financial Reporting Standard ("FRS") 101 'Reduced Disclosure Framework'
The Company is required to change the accounting framework for its entity financial statements and those of its subsidiary, Futura Medical Developments Limited, which have previously adopted United Kingdom Generally Accepted Accounting Standards. From the year ended 31 December 2015 the parent entity and its subsidiaries will adopt FRS 101 'Reduced Disclosure Framework', based on International Financial Reporting Standards as adopted by the European Union.
Objections to the use of the disclosure exemptions may be served by a shareholder or shareholders holding in aggregate 5% or more of the total allotted shares of the Company in writing to Derek Martin, Futura's Finance Director, at the Company's registered office (40 Occam Road, Surrey Research Park, Guildford, Surrey, GU2 7YG) not later than 18 February 2016.
The consolidated financial statements of Futura Medical plc are unaffected by this change and will continue to be prepared in accordance with International Financial Reporting Standards as adopted by the European Union.
Correction to RNS issued 10 September 2015
The total number of ordinary shares held by James Barder following the issue of share options on 9 September 2015 is 1,458,830, as notified by the RNS dated 22 January 2015.
For further information please contact:
Futura Medical plc | |
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
Email to: james.barder@futuramedical.com | www.futuramedical.com |
N+1 Singer (Nominated Adviser and Broker) | |
Aubrey Powell / Liz Yong / Tom Smale | Tel:+44 (0) 20 7496 3000 |
For media enquiries please contact: | |
Buchanan | |
Mark Court / Sophie Cowles / Stephanie Watson | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com